Table 2—

Change from baseline in HbA1c (%) at end point in all patients, patients >64 years, and in patients >64 years with RI* (pooled ITT population from four placebo-controlled studies)

Patient population and treatment groupnBLChange from baseline
Difference from placeboDifference from placebo (P value)
Mean ± SEAdjusted mean ± SE
All patients
 Placebo5218.19 ± 0.050.32 ± 0.050.31 ± 0.05
 Nateglinide 120 mg5448.27 ± 0.05−0.47 ± 0.05−0.48 ± 0.05−0.78 ± 0.07<0.001
Patients >64 years
 Placebo1648.06 ± 0.080.26 ± 0.080.18 ± 0.09
 Nateglinide 120 mg1638.19 ± 0.08−0.64 ± 0.07−0.72 ± 0.10−0.90 ± 0.13<0.001
Patients >64 years with RI*
 Placebo637.99 ± 0.120.25 ± 0.140.41 ± 0.23
 Nateglinide 120 mg608.04 ± 0.12−0.65 ± 0.11−0.73 ± 0.23−1.14 ± 0.340.002
  • Data are means ± SE unless otherwise indicated. RI: calculated creatinine clearance <60 ml/min per 1.73 m2.

  • Results were from an ANCOVA model containing study, treatment, investigative site (nested in study), baseline value, and treatment by baseline.

  • Statistically significantly change from baseline (P < 0.05).